Pharmacia & Upjohn Company

The Upjohn Co.

Other

Pfizer Corporation

Pharmacia Corporation

Scott D Larsen

Paul D May

Valerie Ann Vaillancourt

Martin Durham Meglasson

Heinrich Josef Schostarez

Steven Paul Tanis

John Alan Tucker

Charles H Spilman

Mark E Schnute

Sajiv Krishnan Nair

Karen Rene Romines

Tjeerd Barf

John E Bleasdale

Charlotta Liljebris

David John Anderson

Alice L Laborde

Steven Ronald Turner

Marianne Nilsson

Jerry R Colca

Frank P Bell

James A Nieman

Rolf F Kletzien

Euibong J Kim

Peter K Harris

Howard R Miller

The invention provides a compound of formula I:wherein G, R, and Rhave any of the values defined in the specification, or a pharmaceutically acceptable salt thereof, as well as processes and intermediates useful for preparing such compounds or salts, and methods of treating a herpesvirus infection using such compounds or salts.

Antiviral agents

The invention provides a compound of formula I:wherein G, R, R, and Rhave any of the values defined in the specification, or a pharmaceutically acceptable salt thereof, as well as processes and intermediates useful for preparing such compounds or salts, and methods of preventing or treating a herpesvirus infection using such compounds or salts.

Antiviral compounds

4-oxo-1,4-dihydro-3-cinnolinecarboxamides as antiviral agents

Certain novel 4-hydroxycinnoline-3-carboxyamides. The compounds are particularly effective in the treatment or prevention of viral infections, particularly infections caused by herpes viruses including herpes simplex virus types 1 and 2, human herpes virus types 6, 7 and 8, varicello zoster virus, human cytomegalovirus or Epstein-Barr virus.

4-hydroxycinnoline-3-carboxyamides as antiviral agents

The present invention comprises small molecular weight, non-peptidic inhibitors of formulae I-VII of Protein Tyrosine Phosphatase 1 (PTP1) which are useful for the treatment and/or prevention of Non-Insulin Dependent Diabetes Mellitus (NIDDM).

Inhibitors of protein tyrosine phosphatase

The present invention comprises small molecular weight, non-peptidic inhibitors of formula I and II of Protein Tyrosine Phosphatase 1 (PTP1) which are useful for the treatment and/or prevention of Non-Insulin Dependent Diabetes Mellitus (NIDDM).

The present invention provides novel compounds of the formula I and II for the treatment of non-insulin dependent diabetes mellitius (NIDDM) and a new use of known compounds for this purpose.

Aminoguanidine carboxylates for the treatment of non-insulin-dependent diabetes mellitus

Compounds selected from the group consisting of formulae I, II, III, IV, VI, VII, and VIII

Aminoguanidine carboxylate lactams for the treatment of non-insulin-dependent diabetes mellitus

Compounds selected from the group consisting of formulae III, IV, VI and VIII

The present invention provides for the treatment of non-insulin dependent diabetes mellitus or obesity comprising the systemic administration of a compound having the formula

Aminoquanidine carboxylates for the treatment of obesity

Aminoguanidine carboxylates for the treatment of non-insulin-dependent

The present invention provides novel compounds of the formulae I-VIII for the treatment of non-insulin dependent diabetes mellitus (NIDDM) and a new use of known compounds IX to X for this purpose.

Aminoguanidine carboxylate lactams for the treatment of

The present invention provides some novel 4-hydroxycoumarin-3-carboxamide derivatives and the use of a broad class of 4-hydroxycoumarin-3-carboxamide derivatives for the treatment of a patient suffering from or susceptible to diabetes mellitus.

4-hydroxycoumarin-3-carboxamides for the treatment of diabetes mellitus

Pyrazoloazepino-substituted oximes, having the formula ##STR1## wherein R is ##STR2## where R.sup.5 is --(CH.sub.2).sub.c -- and c is 3-6 are disclosed. These compounds are useful for the treatment of atherosclerosis and hypercholesterolemia.

Growing community of inventors

Kalamazoo, MI, United States of America

Scott D Larsen